Fig. 11

Comparison of experimental results between the H-MRC12a combined detection system and a commercially available QPCR genotyping kit for detecting clinical HPV 31, 33, 35, and 45-positive samples. Clinical samples were heat-inactivated and subjected to nucleic acid extraction using the nanomagnetic bead method. The extracted nucleic acids were then incubated in the H-MRC12a combined detection system for 40 min (Multiple RPA incubation for 20 min, followed by CRISPR incubation for an additional 20 min) and immediately observed under 300 nm UV light. a Fluorescence curves and CT values obtained from the commercially available QPCR genotyping kit for the clinical samples. b Real-time fluorescence signals (recorded using the Q160 LongGene portable QPCR instrument) of the H-MRC12a dual detection system for the clinical samples and negative control after 20 min of incubation in the CRISPR step. c Photographs taken under UV light of the clinical samples of each type incubated for 40 min in the H-MRC12a detection system. S31-1~S31-3: Identification numbers of 3 HPV 31-positive clinical samples; S33-1/S35-1: Identification numbers of HPV 33-positive and HPV 35-positive clinical samples; S31/45: Identification numbers of HPV 31/45 double-positive clinical samples; CRH1~6: Tubes containing crRNA specific for HPV 16, 18, 31, 33, 35, and 45, respectively, for genotyping detection; NC: Negative control